OUR PIPELINE

Aurinia is committed to delivering transformative therapies that address the unmet needs of patients living with autoimmune diseases today – and developing the breakthrough therapies of tomorrow. Our work is rooted in science and at the leading edge of approaches for the treatment of autoimmune and inflammatory diseases. We feel the urgency of finding treatments that enable patients to live their fullest lives and recognize the importance of pursuing research that reflects the diversity of the patients we seek to serve.

Target Discovery & Validation Drug Discovery Lead ID & Optimization IND Enabling Phase 1 Phase 2 Phase 3 U.S. FDA Approval Post-marketing Studies

LUPKYNIS® (voclosporin)

Target Discovery & Validation Phase complete
Drug Discovery Phase complete
Lead ID & Optimization Phase complete
IND Enabling Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase complete
U.S. FDA Approval Phase complete
Post-marketing Studies Phase in progress
Current Phase:
Post-marketing Studies

AUR200

Target Discovery & Validation Phase complete
Drug Discovery Phase complete
Lead ID & Optimization Phase complete
IND Enabling Phase in progress
Current Phase:
IND Enabling
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
U.S. FDA Approval Phase not started
Post-marketing Studies Phase not started

AUR300

Target Discovery & Validation Phase complete
Drug Discovery Phase complete
Lead ID & Optimization Phase complete
IND Enabling Phase in progress
Current Phase:
IND Enabling
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
U.S. FDA Approval Phase not started
Post-marketing Studies Phase not started
Watch this animation to learn more about how AUR200 works.

AUR200

AUR200 is a highly potent and specific immune modulator of BAFF and APRIL activity. BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand) play important roles in regulating B-cell survival and differentiation and have been shown to play a prominent role in the pathogenesis of certain autoimmune and renal conditions.

AUR200 has a proven mechanism of action.

AUR200 is currently undergoing preclinical development with submission of an IND to the FDA projected for 2023

Watch this animation to learn more about how AUR300 works.

AUR300

AUR300 is a novel peptide therapeutic that modulates M2 macrophages (a type of white blood cell) via the macrophage mannose receptor CD206. Dysregulation of M2 macrophages drives fibrosis. Unlike AUR200 and VCS, which target B-cell and T-cell activity of the adaptive immune response, AUR300 targets the innate part of the immune system, specifically M2 macrophages. There is growing recognition that the innate immune system plays a more prominent role in autoimmune disease pathogenesis than may have been previously appreciated. AUR300 acts to reduce M2 dysregulation and decrease inflammatory cytokines and therefore may have significant clinical applications for autoimmune and fibrotic diseases.

AUR300 has a proven mechanism of action.

We anticipate that an IND for AUR300 will be submitted in 2024.

© Aurinia Pharmaceuticals Inc. All Rights Reserved. US-LUP-2300105 08/23
Back to top